Sanofi has divested its central nervous system (CNS) portfolio, which includes 11 brands, to UK-based pharma life cycle management company Pharmanovia.
The brands span four therapy areas of ongoing unmet need associated with CNS disorders – psycholeptic, anxiolytic, anti-epileptic and anti-psychotic. Included in the sale are several benzodiazepines, including Frisium, Sentil and Urbanyl; phenobarbital Gardenal; cyamemazine Tercian; and prochlorperazine Stemetil.
Pharmanovia says the portfolio is available in 60+ markets and will deepen the company's CNS footprint in Brazil, South Africa, France and Italy.
Financial terms were not disclosed.